THE OTHER SIDE. THERE IS ONE,YOU KNOW.
%20(1)%20(4)%20(1).jpg)
Putin made Biden fall! No actually it was Trump's doing:
+++
By Matt Vespa +
+++
+++++++++++++++++++++++++++++
Clever ad:Adminisitration's (Biden) policies are killing Americans:
+++
| CHIP IN HERE >> |
The Biden Administration doesn’t care about protecting Americans and views critics of his Administration as terrorists. In the eyes of this Administration, it’s either put up or SHUT UP.
PROTECT OUR COUNTRY! PROTECT OUR BORDER! SUPPORT BUDDY!
Actual terrorists have been caught trying to cross the border, but in the eyes of the Biden Administration, the real terrorists are concerned parents at school board meetings. This has to stop, and we have to stand up for our rights and, more importantly, the next generation.
.jpg)
+++
Just saw "Top Gun." Tom Cruise keeps cruising and appears ageless. Looks still good, teeth sill white, smile still great. Recommend the movie.
Just saw "Top Gun." Tom Cruise keeps cruising and appears ageless. Looks still good, teeth sill white, smile still great. Recommend the movie.
Forerunner of what IAF pilots may have to do.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Frank Luntz was recently interviewed about what he thinks and learned about the Jan. 6 Hearings and whether it had resonated with voters. His reply, it was structure by Pelosi to be political when it should have been a presentation of facts and then allow voters to decide. Consequently it has been a failure.
+++
Trump lost the election, even though there were shenanigans, particularly in Pa. before the vote. That said, he is right to attack Pelosi's contrived Hearings because it is all sham. Meanwhile, Trump also would do himself some good as well as the party he represents if he would/could move on and suck it up. I believe he cannot because he is obsessed and his ego will not allow. This is his undoing.
Trump lost the election, even though there were shenanigans, particularly in Pa. before the vote. That said, he is right to attack Pelosi's contrived Hearings because it is all sham. Meanwhile, Trump also would do himself some good as well as the party he represents if he would/could move on and suck it up. I believe he cannot because he is obsessed and his ego will not allow. This is his undoing.
+++++++++++++++++
There is plenty of evidence Biden is both out of touch, is actually incompetent and this attached op ed adds more proof. His failure to address the illegal immigration issue makes him impeachable alone.
+++
Biden loves to dump on everyone else when it is his own policies that contribute to what he blames other's for doing.
No one should believe the drug industry has not taken advantage of their critical position but they also must make the approved drugs pay for the research failures. Thus the price of today's pill pays for the pills that did not make it.
+++
Biden May Stop His Cancer Moonshot’s Launch
If drug makers can’t turn a profit owing to his tax and regulatory policies, who’ll develop new treatments?
By Allysia Finley
In his last year as vice president, Joe Biden launched a “cancer moonshot” to accelerate cures for the disease. It was short-lived, but he did help negotiate an agreement in Congress easing regulation of breakthrough drugs and medical devices.
In February, President Biden revived the initiative, setting a goal of reducing cancer death rates by at least 50% over the next 25 years. It’s ambitious but may be achievable given how rapidly scientific knowledge and treatments are advancing. Other Biden policies, however, are at odds with the goals of this one.
Two pharmaceutical breakthroughs were announced only last week that could save tens of thousands of lives each year and redefine cancer care. Yet the tax hikes and drug-price controls that the Biden administration is pitching would discourage the private investment that has delivered these potential cures.
The overall annual cancer mortality rate has fallen 27% over the past two decades. This progress is in part thanks to preventive screenings like mammograms and reduced smoking rates. But much recent progress has come from newer treatments that target specific tumor biomarkers—often a mutated gene or protein—and immunotherapies that harness the immune system to fight cancer. Some biomarkers are unique to individual patients, but scientists have identified some 160 that are shared by some subset of cancer patients. For instance, mutations in the KRAS gene have been found in non–small cell lung, colorectal and pancreatic cancers.
Cancer innovations are accelerating as the gains from research and investment over many years accrue and compound. The risk of death from cancer fell about 2% a year from 2015 through 2019, compared with 1% annually during the 1990s. It is set to fall even faster in coming years as treatments become available for stubborn cancers that resist chemotherapy and radiation.
While common cancers like prostate and breast cancer have a nearly 100% survival rate if caught early, drugmakers and biotech startups are increasingly channeling investment into rare and aggressive forms of the disease. About two-thirds of the 2,335 trials that launched globally last year focused on novel treatments for rare cancers with smaller patient populations. These include glioblastoma, which killed Mr. Biden’s son Beau.
Consider GlaxoSmithKline’s immunotherapy Jemperli, which targets cancers caused by a rare genetic disorder known as mismatch repair deficiency, or dMMR, that tend to be less responsive to chemotherapy and radiation. The Food and Drug Administration granted Jemperli accelerated approval last August after it demonstrated promising results in patients with recurrent or advanced colorectal, small-intestine and stomach tumors caused by dMMR.
But could Jemperli work for other rare cancers? Researchers at Memorial Sloan Kettering Cancer Center with funding from GlaxoSmithKline decided to test the drug on a small group of patients with advanced rectal cancer caused by dMMR. The genetic disorder accounts for 5% to 10% of the 45,000 rectal cancers diagnosed annually.
Oncologists were blown away by the results reported last week in the New England Journal of Medicine: All 12 patients receiving the drug achieved complete remission after six months of treatment. None needed surgery, chemotherapy or radiation. Although some may relapse, the 100% success rate is unprecedented even for a small trial.
Doctors are hopeful that Jemperli might help some patients with pancreatic cancer, which can also be caused by dMMR and is usually a death sentence. Follow-up research and trials often reveal that treatment benefits extend to cancers other than the ones for which they were initially developed. This is how therapies like Merck’s Keytruda—which treats metastatic melanoma, non–small cell lung cancer, Hodgkin lymphoma and bladder cancer, among many others—become blockbusters.
Profit nowadays is a dirty political word, but it is what funds research and creates incentives for drugmakers to study how approved drugs can help different classes of patients.
AstraZeneca’s breast-cancer treatment Enhertu is a monoclonal antibody attached to a chemotherapy drug. Breast cancers are now classified as HER2-positive or -negative based on whether they have an abnormal number of proteins that cause cells to multiply too quickly. Not long ago, HER2-positive breast-cancer patients were at higher risk of recurrence and death. But their survival rates have improved dramatically over the past two decades thanks to HER2-targeting immunotherapies including Enhertu, which the FDA approved in 2019.
Most patients are categorized as HER2-negative. Many actually have a small amount of HER2, and doctors are increasingly describing them as “low HER2” so they could potentially be treated with Enhertu. Though this concept hasn’t been universally accepted, it soon may be.
Last week AstraZeneca in partnership with Daiichi Sankyo reported that Enhertu reduced the risk of death by 36% in patients with metastatic breast cancer with low HER2 and by half for the subset who were hormone-receptor negative. These results blow the outcomes for other metastatic breast-cancer therapies out of the water. Oncologists estimate that Enhertu could reduce disease progression for half of patients now classified as HER2-negative, or about 40% of all breast-cancer patients. They are also hopeful that the drug’s mechanism could be applied to other hard-to-treat cancers.
These treatment breakthroughs aren’t happening because of government programs. They’re happening because pharmaceutical companies have invested decades and hundreds of billions of dollars in drug research and development. It typically takes 10.5 years and $1.3 billion to bring a new drug to market. About 95% of cancer drugs fail.
This is important to keep in mind as Mr. Biden and Democrats in Congress push for Medicare to “negotiate”—i.e., cap—drug prices and raise taxes on corporations and investors. The large profits that drugmakers notch from successful drugs are needed to reward shareholders for their investment risk and encourage future investment. Capital is mobile.
Mr. Biden’s proposal to increase the top marginal individual income-tax rates, including on capital gains, would punish venture capitalists who seed biotech startups, which do most early-stage research on cancer drugs and are often acquired by large drugmakers. At the same time, his proposed corporate global minimum tax would raise costs of intellectual property, which is often taxed at lower rates abroad.
There aren’t many things to celebrate nowadays, but biotech innovation is one. Let’s hope the president doesn’t kill his own cancer moonshot.
Ms. Finley is a member of the Journal’s editorial board.
+++++++++++++++++++++++++++++++++++
Bennett: ‘Our new rule is, whoever sends attackers, pays’
JNS
Addressing Iran’s attempts to harm Israelis abroad, Israeli Prime Minister Naftali Bennett calls on citizens to “show personal responsibility.”
And:
IDF strikes Hamas positions after rocket fired from Gaza
Rocket may have been retaliation for three terrorists killed in Jenin shootout.
By David Hellerman, World Israel News
The IDF struck a number of Hamas targets in the Gaza Strip on Saturday morning after Palestinians launched a rocket in the direction of Ashkelon.
The launch — around 3:00 A.M. — marked the first Palestinian rocket fire at Israel since April. The rocket was intercepted by the Iron Dome. Warning sirens were sounded in a number of Israeli agricultural communities near the border.
None of the Gaza terror groups claimed responsibility for the launch.
The IDF opted to wait till daylight to launch retaliatory strikes. According to the IDF, strikes hit a weapons production facility in central Gaza and three Hamas observation posts along the border.
Hamas quickly returned to one of the damaged border posts, opposite Kibbutz Netiv Ha’asara and hoisted a flag. Residents of the kibbutz were angered that the post wasn’t completely destroyed.
Later on Saturday, the kibbutz was targeted with machine gun fire from the Strip. No Israelis were injured, but one bullet entered a home causing some damage.
As a result of the rocket fire, Israel suspended plans to increase the number of work permits for Palestinians in Gaza. Israeli authorities announced on Thursday that 2,000 additional licenses would be made available for Palestinians seeking work in Israel.
Walla News reported that the rocket may have been fired by Palestinian Islamic Jihad after three of its gunmen were killed in a shootout with IDF forces in Jenin on Friday. An IDF reconnaissance unit operating in Jenin were attacked by gunmen firing guns and throwing explosives from a car.
Eight other Palestinians were injured during the shootout. There were no IDF casualties.
Palestinian media identified the three as Baraa Lahlouh, Laith Abu Srour and Yousef Salah and coverage included photos of all three posing with rifles. Lahlouh was said to be a member of Hamas but the affiliations of the other two weren’t clear.
Also on Friday, an IDF observation balloon crashed down in the Gaza town of Beit Hanoun.
The IDF said the balloon became detached from an anchor while Hamas said it was shot down by machine gun fire. Hamas claimed it captured the balloon along with its cameras and sensors while the IDF said it wasn’t concerned about any technology falling into Palestinian hands.
AND
Iran's Nuclear Program: Where Is the Biden Administration's Plan B?
by Majid Rafizadeh
There exists the dangerous likelihood, if and when Iran's regime has nuclear weapons, that they will fall into the hands of Iran's proxies and militia groups, or that the regime will share its nuclear technology with its proxies and allies, including the Syrian regime and the Taliban in Afghanistan. (Image source: iStock)
The Biden administration's nuclear negotiations to revive the nuclear deal (the Joint Comprehensive Plan of Action) with Iran's ruling mullahs are going nowhere, all while the administration does not seem to have a Plan B.
The ruling mullahs of Iran defiantly continue to advance their nuclear program. They recently switched off two surveillance cameras that were installed by the United Nations' nuclear watchdog, the International Atomic Energy Agency (IAEA), and will reportedly remove at least another 25.
According to a report by Iranian state television, the Iranian government deactivated "beyond-safeguards cameras of the measuring Online Enrichment Monitor ... and flowmeter." By turning off the surveillance cameras, the regime is effectively preventing the IAEA from monitoring Iran's nuclear activities, including its centrifuges and uranium enrichment.
Iran's ruling clerics continue to claim that their nuclear program is designed for peaceful purposes, not for manufacturing nuclear weapons. If this is so, and if Iran's regime does not have anything to conceal when it comes to its nuclear activities, why is it switching off the IAEA surveillance cameras?
While the Biden administration continues to rely on "negotiations", which they are not even themselves negotiating, Iran has enriched a substantial amount of uranium -- up to 60% purity, a short technical step away from the 90% purity level required to build a nuclear weapon. Even France, Germany and the United Kingdom recently warned that the Iranian government's latest action is "further reducing the time Iran would take to break out towards a first nuclear weapon and it is fueling distrust as to Iran's intentions."
In addition, the Biden administration recently acknowledged that Iran is only weeks away from obtaining nuclear breakout capability. Secretary of State Antony Blinken issued the warning last month during a hearing with the Senate Foreign Relations Committee.
The Biden administration must know that Russia and China are not going to pressure Iran's ruling mullahs to cooperate with the IAEA or halt their nuclear activities. In addition, Iran's leaders have shown during the last few years, and during previous rounds of negotiations, that they have absolutely no desire to scale back their nuclear advancements.
If the Biden administration allows Iran to obtain nuclear weapons, President Joe Biden and his associates, like Neville Chamberlain's illusory "Peace for our time," will have as their legacy that it was their acts alone that destabilized global security and set the world at risk.
Iran's ruling clerics, among other unacceptable offenses, have frequently threatened to wipe a whole country, Israel, off the map. One of the core pillars of the Islamic Republic of Iran since the regime took power in 1979 has been the destruction of the Jewish state. Eliminating Israel was not only one of the main religious prophecies of the founder of the Islamic Republic of Iran, Ayatollah Ruhollah Khomeini, it is also a leading policy of his successor, the current Supreme Leader Ayatollah Ali Khamenei, that Israel will be erased from the face of the earth.
There also exists the dangerous likelihood, if and when Iran's regime has nuclear weapons, that they will fall into the hands of Iran's proxies and militia groups, or that the regime will share its nuclear technology with its proxies and allies, including the Syrian regime and the Taliban in Afghanistan. Iran's regime has already been setting up weapons factories abroad, and manufacturing advanced ballistic missiles and weapons in foreign countries, such as in Syria. These weapons include precision-guided missiles with advanced technology to strike specific targets.
It is also important to remember that the Iranian regime's core pillar is anchored in prioritizing the pursuit of its revolutionary ideals: exporting its Islamist system of governance to other countries worldwide, a critical mission the mullahs incorporated into their constitution. "The mission of the constitution," the preamble stipulates, "is to create conditions conducive to the development of man in accordance with the noble and universal values of [Shiite] Islam." Iran's constitution goes on to say that it "provides the necessary basis for ensuring the continuation of the revolution at home and abroad."
It is therefore imperative that the Biden administration let the ruling mullahs know -- credibly -- that Iran's regime must eliminate the possibility of its having nuclear arms, period. No nuclear deal, no sunset clauses. Sunset clauses merely pave the way for Iran to resume enriching uranium at any level it chooses. The regime's ballistic missile program, which is linked to its nuclear program, must also be eliminated.
The Biden administration needs immediately to carry out its Plan B. It has to be made clear to the Iranian regime that, as part of Plan B, military options against the Iran's nuclear sites are on the table. It must be made unmistakably clear to the Iranian regime that the United States and its allies will not allow the current regime, a state sponsor of terrorism, to arm itself with nuclear weapons and emerge as yet another global nuclear threat.
Dr. Majid Rafizadeh is a business strategist and advisor, Harvard-educated scholar, political scientist, board member of Harvard International Review, and president of the International American Council on the Middle East. He has authored several books on Islam and US foreign policy. He can be reached at Dr.Rafizadeh@Post.Harvard.Edu
++++++++++++++++++++
Hillary Clinton Plays the Victim, Claims She Is the 'Most Investigated Innocent Person in America'
By Sarah Arnold
+++++++++++++++++
Biden purposely keeps chipping away at Trump's triumphs. What a pissie fanny person he is.
+++
Biden Nominees Backtrack on Abraham Accords, Israeli-Election Interference
Two Biden administration nominees for top posts related to the Middle East came under fire for alleged anti-Israel bias by Senate Republicans in their confirmation hearing on Thursday.
The hearing, held in the Senate Foreign Relations Committee, comes at a critical time as U.S. President Joe Biden is expected to travel to Israel and Saudi Arabia next month while the United States is struggling to repair its frayed relationship with the Arab kingdom amid skyrocketing gas prices.
Sen. Ted Cruz (R-Texas) took issue with Tamara Cofman Wittes, the nominee for assistant administrator for the Middle East at the U.S. Agency for International Development (USAID), which is responsible for distributing aid for development in the Middle East.
Cruz said that rather than a confirmation hearing, the Democratic majority convened a hearing on the “profound anti-Israel bias of the Biden administration.”
During questioning, Cruz pointed to Cofman Wittes’s controversial past of being highly critical of the Abraham Accords during the Trump administration, according to the Washington Free Beacon.
“Why were you urging Arab countries not to deepen ties with Israel?” he asked, referring to a September 2020 tweet, reported by the Washington Free Beacon, where she wrote: “If I were an Arab leader weighing ties with Israel, I would have 2 things in mind. 1) A promise from [Trump adviser Jared] Kushner now isn’t worth much. Why not wait until after Nov elections? 2) Bibi’s backtracked on his commitments to UAE; his promises aren’t worth much either. Let’s wait & see … ”
“I was skeptical when the Emiratis made their announcement, which was breathtaking in August 2020,” she replied. “I was skeptical that other Arab states would join them. I was proven wrong.”
In her opening statement, Cofman Wittes praised the Abraham Accords, calling them a “foundation for more cooperation between Arab states and Israel on shared interests, including on development.” She added that if confirmed, she would help “build on the Abraham Accords to bolster positive engagement across the region on issues like energy, environment, water and health.”
Key pillar of our foreign policy’
Ranking member Sen. Todd Young (R-Ind.) asked her to reconcile her earlier views on the Abraham Accords with her current support.
Young mentioned that Cofman Wittes had retweeted an article that called the Abraham Accords misogynistic, a “triumph for authoritarianism” and a “new naksa,” Arabic for “setback.”
“I was wrong about that,” she replied. “We’ve seen Morocco, we’ve seen Sudan, we’ve seen Bahrain come, and that, I think, creates a tremendous opportunity that we need to seize.”
Cruz claimed that Wittes’s former employer, the Brookings Institution, had publicly revealed it took millions in funding from Qatar. He also noted that the former president of the Washington-based think tank, retired Marine Gen. John R. Allen, has recently resigned after reports that the FBI was investigating allegations that Allen lobbied on behalf of Qatar without registering as a foreign agent.
When asked to what extent she participated in fundraising for Qatar by Cruz, she replied that she had no knowledge of Allen’s activities.
While she claimed that she knew that Qatar funded work produced by the institution, she insisted that it played no role in the research and that she only once participated in a fundraising meeting with Qatari representatives in 2012, but it was under former Brookings executive vice president Martin Indyk.
“I want to be very clear, I had no knowledge of any of these disturbing allegations regarding General Allen,” she said. “I didn’t discuss research on Qatar with General Allen. I did not do fundraising meetings for foreign governments with General Allen.”
Cofman Wittes insisted that despite Brookings’ projects being funded by Qatar, her research and the research she supervised were completely independent of international donors.
‘Wrapped within our values’
Michael Ratney, current Chargé d’Affaires of the U.S. embassy in Israel, who is nominated for the post of ambassador to Saudi Arabia, had a slightly less contentious time during the hearing, despite the importance of his role in the current climate.
He said that he was going to continue building on the relationship between Saudi Arabia and the United States while staying in line with the Biden administration’s focus on human rights as a “key pillar of our foreign policy.”
Sen. Ben Cardin (D-Md.) echoed some of the priorities laid out by Ratney in his opening statements, mentioning the need for progress towards normalization between Saudi Arabia and Israel, “but this all needs to be wrapped within our values.”
Sen. Bill Hagerty (R-Tenn.), who himself served as ambassador to Japan in the Trump administration, asked Ratney about an incident during his time as U.S. Consul General in Jerusalem from 2012 to 2015, where American taxpayer funds provided as grants to a pro-Democracy organization in the region ended up being used to oppose then Israeli Prime Minister Benjamin Netanyahu’s re-election bid.
“Under your watch, the State Department provided $465,000 in grants to a group called OneVoice, which then joined a group called Victory 15 and worked to defeat Benjamin Netanyahu and his Likud Party in Israel’s elections,” said Hagerty. “This struck many observers, including me, as highly inappropriate, if not unethical, especially given that the Obama administration disagreed with Netanyahu and his many policies, including the Iran nuclear deal.”
Hagerty asked Ratney how he did not foresee and guard against the risk that U.S. State Department funding would go towards political activism.
Ratney said he was only responsible for oversight of the “Palestinian component” of the grant to OneVoice, which was going towards building “grassroots support for a two-state solution” and the negotiating process underway at the time.
Hagerty then asked if Ratney disputed findings in a report on the incident by the Senate Committee on Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations that he deleted emails related to the review of OneVoice grants.
Ratney said that this finding by the investigation was the result of a systematic issue at the State Department at that time, where there was no requirement to archive all of the routine emails that the State Department sent or received.
“At the time, the State Department—the email systems didn’t have the storage capacity to retain large numbers of emails in people’s inboxes. This was not unique to me,” said Ratney. “We were routinely instructed by our IT staff that if you don’t delete emails, especially those with large attachments, your inbox freezes and you stop getting emails. So that was a systemic problem that was addressed both by improvements in the technology and also a change to the policy about archiving of these messages.”
+++++++++++++++++
Mickey and Disney have some egg on their face.
+++
No comments:
Post a Comment